MDR Pathogens Organisms as Risk Factor of Mortality in Secondary Pulmonary Bacterial Infections Among COVID-19 Patients: Observational Studies in Two Referral Hospitals in West Java, Indonesia

Prayudi Santoso1, Martina Sung1, Yovita Hartantri1, Basti Andriyoko2, Adhi K Sugianli2, Bachti Alisjahbana1, Jeanne Sian Lie Tjiam3, Josephine Debora1, Dewi Kusumawati3, Arto Yuwono Soeroto1

1Internal Medicine Department, Hasan Sadikin General Hospital, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia; 2Clinical Pathology Department, Hasan Sadikin General Hospital, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia; 3Santo Borromeus Hospital, Bandung, Indonesia

Correspondence: Prayudi Santoso, Internal Medicine Department, Hasan Sadikin General Hospital, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia, Tel +62-22-2038986, Email prayudi@unpad.ac.id

Purpose: The coronavirus disease (COVID-19) outbreak has created a global health crisis. Secondary pulmonary bacterial infection is a COVID-19 complication, increasing morbidity and mortality. This study aimed to determine the pathogens, antibiotic susceptibility patterns, and risk factors for mortality in hospitalized COVID-19 patients.

Patients and Methods: This retrospective study used secondary data from patients’ electronic medical records at Hasan Sadikin General Hospital and Santo Borromeus Hospital between March 2020 and March 2021. Overall, 2230 hospitalized COVID-19 patients were screened, and 182 of them who were hospitalized ≥48 hours with a procalcitonin level of ≥0.25 ng/mL were enrolled. Culture examination was performed on sputum samples to determine pathogen and antibiotic susceptibilities. Univariate and multivariate analyses were used to determine mortality-related risk factors in hospitalized COVID-19 patients.

Results: The prevalence of secondary pulmonary bacterial infections in COVID-19 patients was 8.2%, with 161/182 pathogen growth from sputum samples. Mainly gram-negative bacteria (64.8%) were present, including Acinetobacter baumannii (31.9%), Klebsiella pneumoniae (19.8%), and Pseudomonas aeruginosa (8.8%). High rate of multidrug-resistant (MDR) pathogens was found among isolate (45.9%), ie carbapenem-resistance A.baumannii (CR-Ab) was 84.2%, extended-spectrum β-lactamase (ESBL) among K. pneumoniae was 61.1%. Secondary infection of MDR pathogens was associated with a higher risk of mortality (AOR 5.63, p = 0.001). Other associated factors were age ≥60 years, ventilator use, and female gender.

Conclusion: Gram-negative bacteria are the predominant pathogens causing secondary pulmonary bacterial infection in COVID-19 patients, implying nosocomial infection. High resistance to first-line antimicrobial drugs was observed in Gram-negative bacteria and Gram-positive bacteria. High rate of MDR pathogens was found among isolate and was associated with a significant risk of mortality.

Keywords: COVID-19, secondary pulmonary bacterial infection, antibiotic susceptibility, MDR pathogens, West Java, Indonesia

Introduction

The outbreak of coronavirus disease (COVID-19) has created a global health crisis and has become the largest pandemic in human history. From December 31, 2019, until mid-November 2021, a total of 257,904,476 COVID-19 cases have been reported, including 5,163,335 COVID-19-associated deaths.1 A high mortality rate was reported early in the pandemic, with nearly 36% of patients dying between January and February 2020 in China,2 and previous studies in
Indonesia reported an overall mortality of 9.4% and 12%. Mortality has been associated with older age, pre-existing comorbidities, disease severity, admission to the intensive care unit (ICU), and ventilator use. In addition to the risk factors mentioned, secondary pulmonary bacterial infection has been identified as a common complication of viral respiratory infection, which increases morbidity and mortality.

A similar pattern was observed in previous viral pandemics. The 1918 Spanish flu pandemic resulted in 50 million deaths worldwide, with the majority of deaths attributable to secondary bacterial pneumonia. During the 2009 H1N1 pandemic, secondary bacterial infections were detected in 18–34% of influenza cases, with incidence peaking at 1 week after influenza infection. Studies conducted in China, Hong Kong, and Mexico reported that bacterial secondary infections in COVID-19 patients were observed only in 6–12% of patients. One meta-analysis of COVID patients from 2019 to April 2020 also showed the overall proportion of bacterial infection in COVID patients was 6.9% (95% CI 4.3–9.5%), with a higher proportion being observed in critically ill patients.

However, early in the pandemic, empiric treatment for bacterial secondary infections in hospitalized COVID-19 patients was common, especially with penicillin and macrolide agents, which were recommended as first-line treatments for community-acquired pneumonia. A meta-analysis showed that 71.9% of patients hospitalized with COVID-19 before mid-April 2020 received antibiotics. Improper administration of antibiotics will increase antibiotic resistance, which, in turn, will increase mortality in COVID-19 patients. Secondary bacterial pulmonary infections need to be recognized and treated effectively to reduce antibiotic resistance, which is increasing at an alarming rate. Previous studies in Brazil analyzed bacterial infections in patients with severe COVID, and already reported multi-drug resistance was present in 96% of A. baumannii and 57% of K. pneumoniae that were associated with longer ICU stay, mechanical ventilation use, and higher mortality. Currently, there are limited studies on secondary infections and antimicrobial use in COVID-19 patients in Indonesia. Therefore, this study aimed to determine the pathogens of secondary pulmonary bacterial infection, antibiotic susceptibility, and risk factors for mortality in COVID-19 patients admitted in two referral hospitals in West Java, Indonesia.

**Methods**

**Study Design and Participants**

This retrospective study used secondary data extracted from the medical records of hospitalized patients with confirmed COVID-19 between March 2020 and March 2021. This study was carried out at two referral hospitals in Bandung: Hasan Sadikin Hospital, a public hospital with 944 inpatient services, and Santo Borromeus Hospital, a large private hospital with 394 inpatient services. Both hospitals included nearly 70 ICUs. Patients with confirmed COVID-19 were identified based on clinical signs and symptoms and the detection of severe acute respiratory syndrome coronavirus 2 in polymerase chain reaction assay.

We enrolled confirmed COVID-19 patients with secondary bacterial infection, defined as confirmed COVID-19 patients aged >18 years old and a procalcitonin (PCT) level of up to ≥0.25 ng/mL at 48 hours or more during hospitalization. Patients with other conditions, such as human immunodeficiency virus, acquired immunodeficiency syndrome, pregnancy, autoimmune diseases, malignancy, and urinary tract infection, were excluded from the study.

**Data Collection**

Data were extracted by two authors and cross-checked by another author. Data were extracted from medical records and kept anonymous. Data on the following variables were extracted: age, sex, body mass index, comorbidity, severity, oxygen support, laboratory findings, antibiotic history, and outcome. Pathogen and antibiotic susceptibility data from sputum cultures were also collected. Sputum culture data used in this study were the first sputum cultures obtained from the patient. Sputum samples in which epithelial cells were more than 10 cells per large visual field regardless of the number of leukocytes were not processed for culture. Bacterial and fungal identifications were performed in the microbiology laboratory of each hospital using the Vitek 2 Compact platform (BioMerieux, Marcy L’Etoile, France). Antimicrobial susceptibility testing for bacterial and fungi was performed using Minimum-Inhibitory Concentration (MIC) using the Vitek platform and reported according to the Clinical and Laboratory
Standards Institute (CLSI) guideline 2020 (M100 and M60). The antimicrobial susceptibility (AST) results were interpreted as susceptible, intermediate, or resistant according to the CLSI breakpoint. We also used the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoint, if the breakpoint of certain antimicrobial drugs was not available at CLSI. An intermediate test result was considered resistant. A cumulative AST report was generated using WHOnet software, according to the World Health Organization (WHO) Global Antimicrobial Resistance and Use Surveillance System (WHO GLASS) recommendation. Susceptibility results of cumulative AST were reported as the number of isolates tested and percentage.

All statistical analyses were performed using IBM SPSS, version 26.0 (SPSS, Chicago, Illinois, USA). Variables associated with mortality in the hospitalized patients were analyzed using univariate and multivariate logistic regression models, with p-values of <0.05 considered statistically significant.

Definition
Secondary bacterial infection was defined as a PCT level of up to ≥0.25 ng/mL at 48 hours or more during hospitalization. Hypertension was defined as a blood pressure of ≥140/90 mmHg. Obesity was defined according to the WHO's proposed classification of weight in adult Asians, that is, a body mass index of ≥25 kg/m². Type 2 diabetes mellitus was defined as a fasting plasma glucose level of more than 126 mg/dL (7.0 mm/L) or HbA1C ≥6.5. Chronic kidney disease was defined as either kidney damage or a decreased glomerular filtration rate of <60 mL/min/1.73 m² for at least 3 months. MDR pathogens are defined as pathogens that acquire non-susceptibility to at least one agent in three or more antimicrobial categories. Severe COVID-19 was defined as oxygen saturation below 90% at room air, or respiratory rate of >30 breaths/min, or partial pressure of oxygen (PaO₂)/fraction of inspired oxygen (FiO₂) ratio <300, and/or lung infiltrates >50% within 24–48 hours.

Ethical Considerations
This study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of Hasan Sadikin Hospital and Santo Borromeus Hospital (ethics approval number LB 02.01/X.6.5/83/2021, May 12, 2021, and 014/KEPK/VI/2021, June 3, 2021). Informed consent was not required for this secondary use of medical data; thus, the need for written patient consent was waived by the ethics committee.

Results
In this study, we screened 2230 confirmed COVID-19 patients and enrolled 182 confirmed COVID-19 patients with secondary infection (Figure 1). The prevalence of secondary pulmonary infections was 8.2% (182 of 2230 patients). The baseline patient characteristics are presented in Table 1 and Supplementary Table 1.

Median patient age was 60 years (range–46–69 years). Most of the patients were male (64.3%). Comorbidities were present in more than half of the patients (76.9%), with hypertension being the most prevalent (47.8%), followed by obesity (45.6%) and type 2 diabetes mellitus (35.2%). The increase in PCT levels mostly occurred on the sixth day of hospitalization, with the levels ranging from 0.67 ng/mL to 4.39 ng/mL (median: 1.27 ng/mL). Seventy COVID-19 patients (38.5%) received empirical antibiotics, while the remaining 112 patients (61.5%) did not. The most commonly used antibiotics were third-generation cephalosporins (38.5%), fluoroquinolones (37.9%) and carbapenems (18.1%). The length of hospital stays for COVID-19 patients with secondary pulmonary infections, ranged from 9 to 18 days, with a median of 13 days. The mortality rate of COVID-19 patients with secondary pulmonary infection was as high as 48.4%.

Bacterial growth had a predominance of gram-negative bacteria (64.8%), whereas the growth of gram-positive bacteria was 9.3%, and fungal growth was 8.7%. The three most common gram-negative bacteria were A. baumannii (31.86%), K. pneumoniae (19.78%), and P. aeruginosa (8.79%) (Table 2). MDR strains were found in 74 out of 182 (40.5%) pathogens of secondary pulmonary infection in this study. More than half of A. baumannii and coagulase-negative Staphylococcus were found to have MDR strains, followed by P. aeruginosa (43.7%). Ventilator-acquired pneumonia was particularly related to gram negative bacterial infections. Half of which were caused by infections of A. baumannii and 13.1% were caused by K. pneumoniae infections (Table 2).
High resistance to antimicrobial drugs (≥80%) that are used as the first-line treatment (fluoroquinolone, cephalosporin) for bacterial pneumonia was observed among gram-negative bacteria. This also indicates the MDR-organisms, ie extended-spectrum β-lactamase (ESBL) among *K. pneumoniae* was shown to be 61.1%, Carbapenem-resistance *A. baumannii* was found to be 84.2%, and Carbapenem-resistance *P. aeruginosa* was found to be 50% (Table 3). Meanwhile, the resistance of fluoroquinolone (levofloxacin, ciprofloxacin, moxifloxacin) among *coagulase-negative Staphylococcus* (CoNS) and *Staphylococcus aureus* were ranging between 33.3% and 100%. The *methicillin-resistant coagulase-negative Staphylococcus* (MRCoNS) was observed in all isolates, while *methicillin-resistant Staphylococcus aureus* (MRSA) was observed to be as high as 33.3%. Among MRCoNS, vancomycin-resistance was observed to be as high as 14.1% (Table 4).

Univariate logistic regression analysis revealed patients that had a secondary infection of MDR strains pathogen had a higher risk of mortality (odds ratio [OR] 4.94, 95% confidence interval [CI] 2.17–11.24, \( p < 0.001 \)). Other factors related with higher risk of mortality were ventilator use during hospitalization (OR 4.34, 95% CI 1.58–11.95, \( p = 0.003 \)), followed by older than 60 years (OR 3.12, 95% CI 1.50–6.51, \( p = 0.002 \)) and patients with severe COVID-19 (OR 1.07, 95% CI 1.07–4.52, \( p = 0.03 \) (Table 5). Multivariate logistic regression analysis also demonstrated that the main risk factors associated with mortality were MDR strains pathogen infection, ventilator use during hospitalization, and patients older than 60 years (Table 6).

**Discussion**

Viral infections in the respiratory tract increase susceptibility to secondary bacterial infections through dysregulation of the host immune system, reduced pulmonary mucociliary clearance, and increased bacterial adhesion to the epithelial cells.\(^3\),\(^4\) This study found that the prevalence of secondary pulmonary bacterial infection in COVID-19 patients lower than that in the previous Spanish flu and H1N1 pandemic.\(^9\),\(^11\),\(^12\) The prevalence of secondary pulmonary bacterial infection in COVID-19 patients in this study was 8.2%, which is in concordance with the findings of previous studies that reported a prevalence of secondary infections ranging from 6% to 14% in COVID-19 patients.\(^14\),\(^15\),\(^33\)

Empirical antibiotic therapy was widely used in the early pandemic, mainly because of concerns arising from previous pandemic experiences with high rates of mortality caused by secondary pulmonary bacterial infection.\(^14\),\(^34\) Some studies reported high empiric antibiotic therapy administered to more than 50% of hospitalized COVID-19 patients worldwide.\(^5\),\(^33\),\(^35\) This study found that most patients (70.3%) did not receive empiric antibiotics because the use of
**Table 1 Clinical Characteristics of COVID-19 Inpatients**

| Characteristic                                                                 | Total (n = 182) |
| ------------------------------------------------------------------------------- |-----------------|
| **Age, median (IQR), years**                                                   | 60 (46–69)      |
| **Age group, n (%), years**                                                    |                 |
| ≥60                                                                            | 92 (50.5)       |
| <60                                                                            | 90 (49.5)       |
| **Sex, n (%)**                                                                |                 |
| Male                                                                           | 117 (64.3)      |
| Female                                                                         | 65 (35.7)       |
| **Comorbidities, n (%)**                                                       |                 |
| Any                                                                            | 140 (76.9)      |
| Hypertension                                                                   | 87 (47.8)       |
| Obesity                                                                        | 83 (45.6)       |
| Type 2 DM                                                                      | 64 (35.2)       |
| Chronic kidney disease                                                         | 57 (31.3)       |
| Cardiovascular diseases                                                        | 52 (28.6)       |
| Stroke                                                                         | 13 (7.1)        |
| No comorbidities                                                               | 42 (23.1)       |
| **Time from illness onset to hospital admission, median (IQR), days**         | 3 (2–5)         |
| **Duration of hospitalization, median (IQR), days**                            | 13 (9–18)       |
| <13 days                                                                       | 88 (48.4)       |
| ≥13 days                                                                       | 94 (51.6)       |
| **Laboratory findings, median (IQR)**                                          |                 |
| Procalcitonin                                                                  | 1.27 (0.67–4.39)|
| Days of PCT measurement                                                        | 6 (5–8)         |
| **Oxygen support (%)**                                                         |                 |
| Nasal cannula                                                                  | 57 (33.7)       |
| Non-rebreathing mask                                                           | 40 (23.7)       |
| Ventilator                                                                     | 30 (17.8)       |
| High-flow nasal cannula                                                        | 20 (11.8)       |
| Without oxygen support                                                         | 18 (10.7)       |
| Simple mask                                                                    | 4 (2.4)         |
| **Antibiotics history, n (%)**                                                 |                 |
| No                                                                              | 112 (61.5)      |
| Yes                                                                             | 70 (38.5)       |

(Continued)
complete blood count, PCT, and evaluation of clinical signs of infection as guidance was quickly implemented by the special task team in both hospitals so that antibiotics were not given promptly from the beginning or were stopped immediately in less than 24 h of administration. The mortality rate of COVID-19 patients with secondary pulmonary infection in this study was as high as 48.4%, similar to the findings of other studies conducted in India and China.\(^5\),\(^13\),\(^36\)

Along with the development of knowledge about COVID-19, the management of patients at the beginning of the pandemic may have been different, resulting in a higher mortality rate.

The growth of the pathogens in this study showed predominance of gram-negative bacteria, with the most common species being \textit{A. baumannii}, \textit{K. pneumoniae}, and \textit{P. aeruginosa}. These pathogens are closely associated with nosocomial infection. These findings are similar to those in some studies that showed that the most common pathogens in the group of gram-negative bacteria were \textit{A. baumannii} and \textit{K. pneumoniae}.\(^13\),\(^36\),\(^37\) A study showed different results, with the most common pathogens being \textit{Mycoplasma} sp., \textit{Haemophilus influenzae}, and \textit{Pseudomonas aeruginosa}.\(^16\) One of the reasons for the differences in the bacterial patterns in these studies may be related to the differences in bacterial colonization in each hospital and the differences in patients’ baseline characteristics. Other microorganisms found in this study were \textit{Staphylococcus epidermidis} (2 patients), \textit{Staphylococcus hominis} (2 patients), \textit{Streptococcus sanguinis} (2 patients), \textit{Streptococcus gordonii} (1 patient), \textit{Citrobacter koseri} (1 patient), and fungal organisms (16 patients). A previous study conducted in India reported fungal infections as much as 9%.\(^36\) In this study, we found a similar prevalence of 8.7% fungal infections in hospitalized patients. The fungal organisms found in this study were \textit{Candida albicans} (10 patients), \textit{Candida tropicalis} (4 patients), and \textit{Candida glabrata} (2 patients).

| Characteristic | Total (n = 182) |
|---------------|----------------|
| Outcome, n (%)|                |
| Survivor      | 94 (51.6)      |
| Nonsurvivor   | 88 (48.4)      |

Abbreviations: COVID-19, coronavirus disease; IQR, interquartile range; PCT, procalcitonin; DM, diabetes mellitus.

Table 2 Pathogens of Secondary Pulmonary Infection

| Pathogens                | Total n = 182 (%) | MDR Pathogens n = 74 (%) | HAP n = 136 (%) | VAP n = 46 (%) |
|--------------------------|-------------------|--------------------------|----------------|---------------|
| \textit{Acinetobacter baumannii} | 58 (31.9)         | 42 (72.4)                | 35 (25.7)      | 23 (50.0)     |
| \textit{Klebsiella pneumoniae} | 36 (19.8)         | 14 (38.8)                | 30 (22.1)      | 6 (13.1)      |
| \textit{Pseudomonas aeruginosa} | 16 (8.8)          | 7 (43.7)                 | 13 (9.5)       | 3 (6.4)       |
| \textit{Enterobacter cloacae} | 6 (3.3)           | 0                        | 5 (3.6)        | 1 (2.1)       |
| \textit{Stenotrophomonas maltophilia} | 2 (1.1)          | 0                        | 1 (0.7)        | 1 (2.1)       |
| \textit{Coagulase-negative Staphylococcus} | 12 (6.6)        | 10 (83.3)                | 11 (8.1)       | 1 (2.1)       |
| \textit{Staphylococcus aureus} | 5 (2.7)           | 1 (20)                   | 3 (2.1)        | 2 (4.2)       |
| \textit{Enterococcus faecalis} | 2 (1.1)           | 0                        | 1 (0.7)        | 1 (2.1)       |
| Others                   | 24 (13.2)         | 0                        | 18 (13.3)      | 6 (13.1)      |
| No growth                | 21 (11.5)         | -                        | 19 (13.9)      | 2 (4.2)       |

Notes: Others are \textit{Staphylococcus epidermidis}, \textit{Staphylococcus hominis}, \textit{Streptococcus sanguinis}, \textit{Streptococcus gordonii}, \textit{Citrobacter koseri}, \textit{Candida albicans}, \textit{Candida tropicalis}, and \textit{Candida glabrata}.

Abbreviations: MDR, multidrug resistance; HAP, hospital-acquired pneumonia; VAP, ventilator-acquired pneumonia.
Antibiotic resistance has become a worldwide concern because it causes fatal therapeutic failure, particularly in critically ill patients. The growth rate of MDR bacteria in the samples from the two hospitals was 74 samples (45.9%). Some studies found that more than 50% of MDR and extensively drug-resistant (XDR) strains were found in *A. baumannii* and *K. pneumoniae* isolated from COVID-19 patients admitted in the ICU, with a significantly higher proportion after the pandemic than that before the pandemic. The increasing spread of MDR strains of nosocomial pathogens, especially *A. baumannii*, is likely due to the increase in required interventions for COVID-19 patients, antibiotics overuse, and aggravated by the decline in hygiene protocols in hospitals.

High resistance to antimicrobial drugs that are used as the first-line treatment for bacterial pneumonia was observed in this study, especially among gram-negative bacteria. Some studies showed similar results about increased resistance toward antimicrobial targeting of gram-negative bacteria, especially MDR pathogens. High rate of MDR pathogens was found among isolate, extended-spectrum β-lactamase (ESBL) among *K. pneumoniae* was shown to be 61.1%, Carbapenem-resistance *A. baumannii* was found to be 84.2%, and Carbapenem-resistance *P. aeruginosa* was found to be 50%. One study also reported similar results that *A. baumannii* was not susceptible to almost all of the antibiotics tested, with the highest resistance to ceftazidime (96%), followed by meropenem (94%), fluoroquinolones (93.5%), imipenem (92%), and piperacillin/tazobactam (91%). *K. pneumoniae* showed no susceptibility to third-generation cephalosporins, ceftriaxone (91.7%), fluoroquinolones (82%), β-lactamases, piperacillin/tazobactam (79.2%), and cefoperazone-sulbactam (76.4%).

### Table 3 Antibiotic Susceptibility of Gram-Negative Bacteria

| Antibiotics                  | *Acinetobacter baumannii* | *Klebsiella pneumonia* | *Pseudomonas aeruginosa* | *Enterobacter cloacae* | *Stenotrophomonas maltophilia* |
|------------------------------|----------------------------|------------------------|-------------------------|------------------------|-------------------------------|
|                             | n  | %S | n  | %S | n  | %S | n  | %S | n  | %S |
| Amikacin                    | 58 | 57.9 | 36 | 72.2 | 16 | 62.5 | 6  | 100 | -  | -  |
| Ampicillin-sulbactam        | 58 | 5.9  | 36 | 21.4 | -  | -   | 6  | 0   | -  | -  |
| Aztreonam                   | 58 | 21.7 | 36 | 38.9 | 16 | 56.3 | 6  | 66.7 | -  | -  |
| Cefazolin                   | 58 | 0    | 36 | 0   | 16 | 0   | 6  | 0   | -  | -  |
| Cefepime                    | 58 | 2.9  | 36 | 50  | 16 | 37.5 | 6  | 50  | -  | -  |
| Cefotaxime                  | 58 | 17.4 | 36 | 52  | 16 | 37.5 | 6  | 100 | -  | -  |
| Ceftazidime                 | 58 | 2.9  | 36 | 28.6 | 16 | 37.5 | 6  | 50  | -  | -  |
| Ceftriaxone                 | 58 | 7    | 36 | 38.9 | 16 | 37.5 | 6  | 83.3 | -  | -  |
| Ciprofloxacin               | 58 | 14   | 36 | 38.9 | 16 | 50  | 6  | 83.3 | -  | -  |
| Ertapenem                   | 58 | 39.1 | 36 | 72.2 | 16 | 62.5 | 6  | 100 | -  | -  |
| Gentamicin                  | 58 | 17.5 | 36 | 58.3 | 16 | 62.5 | 6  | 83.3 | -  | -  |
| Levofoxacin                 | 58 | 30.4 | 36 | 50  | 16 | 62.5 | 6  | 100 | 2  | 50 |
| Meropenem                   | 58 | 15.8 | 36 | 72.2 | 16 | 50  | 6  | 100 | -  | -  |
| Moxifloxacin                | 58 | 30.4 | 36 | 50  | 16 | 62.5 | 6  | 100 | -  | -  |
| Piperacillin-tazobactam     | 58 | 2.9  | 36 | 42.9 | 16 | 37.5 | 6  | 50  | -  | -  |
| Tigecycline                 | 58 | 52.6 | 36 | 80.6 | 16 | 25  | 6  | 83.3 | -  | -  |
| Trimethoprim-sulfamethoxazole| 58 | 52.6 | 36 | 44.4 | 16 | 50  | 6  | 83.3 | 2  | 50 |

**Abbreviations:** %S, percentage susceptibility; n, number of isolate tested to certain antimicrobial drugs; −, not tested.
or critically severe COVID-19. Patients required intensive care, mechanical ventilation, steroid therapy, and more exposure to broad-spectrum antibiotics.

*Enterobacter* *baumannii* is one of the most important pathogens associated with nosocomial infections and remains a major concern owing to the rapid development of resistance to various antimicrobials and the ability to survive in the environment for a very long time.47

The majority of *A. baumannii* strains were isolated from the respiratory tract of hospitalized patients, and it is the second most common gram-negative bacteria found in ICUs; the associated mortality rates are as high as 30%–75%.44–46

The high MDR isolate finding rate of *A. baumannii* and *P. aeruginosa* indicates poor environmental conditions associated with the patient, such as poor hand hygiene, poor infection control practices, and

| Antibiotics                        | Coagulase-Negative Staphylococcus | Staphylococcus aureus | Enterococcus faecalis |
|-----------------------------------|-----------------------------------|----------------------|-----------------------|
|                                   | n | %S | n | %S | n | %S |
| Amoxicillin-clavulanic acid       | 12 | 0  | 5 | 0  | -  | -  |
| Ampicillin                        | 12 | 0  | 5 | 0  | 2  | 100 |
| Clindamycin                       | 12 | 100| 5 | 66.7| -  | -  |
| Erythromycin                      | 12 | 0  | 5 | 66.7| 2  | 0   |
| Levofloxacin                      | 12 | 0  | 5 | 66.7| -  | -  |
| Linezolid                         | 12 | 57.2| 5 | 66.7| 2  | 100 |
| Moxifloxacin                      | 12 | 0  | 5 | 66.7| -  | -  |
| Oxacillin                         | 12 | 0  | 5 | 66.7| -  | -  |
| Penicillin                        | 12 | 0  | 5 | 0   | -  | -  |
| Piperacillin-tazobactam           | 12 | 0  | 5 | 0   | -  | -  |
| Tetracycline                      | 12 | 51.5| 5 | 66.7| 2  | 50  |
| Tigecycline                       | 12 | 85.7| 5 | 100 | 2  | 100 |
| Trimethoprim-sulfamethoxazole     | 12 | 68.7| 5 | 100 | 2  | 0   |
| Vancomycin                        | 12 | 85.9| 5 | 100 | 2  | 100 |

**Abbreviations:** %S, percentage susceptibility; n, number of isolate tested to certain antimicrobial drugs; --, not tested.

| Variable                  | Survived (n = 64) | Died (n = 60) | p-value | Crude OR (95% CI OR) |
|---------------------------|-------------------|---------------|---------|----------------------|
| Age (≥60 years)           | 25 (39.1)         | 40 (66.7)     | 0.002*  | 3.12 (1.50–6.51)     |
| Sex (female)              | 19 (29.7)         | 28 (46.7)     | 0.051   | 2.07 (0.99–4.34)     |
| Comorbidity (any)         | 47 (73.4)         | 45 (75.0)     | 0.876   | 1.09 (0.49–2.43)     |
| Ventilator                | 6 (9.8)           | 18 (32.1)     | 0.003*  | 4.34 (1.58–11.95)    |
| Severity (severe)         | 27 (42.2)         | 37 (61.7)     | 0.030*  | 2.21 (1.07–4.52)     |
| MDR pathogens             | 29 (45.3)         | 45 (80.4)     | <0.001* | 4.94 (2.17–11.24)    |

**Note:** *Statistically significant.

**Abbreviations:** OR, odds ratio; CI, confidence interval; COVID-19, coronavirus disease.
lack of adherence to hygiene protocols. Hand hygiene practices are severely affected during the COVID-19 pandemic because all health workers have been using gloves as part of their personal protective equipment. Continuous and inappropriate use of gloves can cause cross-contamination and affect the rate of nosocomial infection.

This study showed that MDR strains pathogen infection, ventilator use during hospitalization, and older age were associated with a higher risk of mortality during hospitalization. In concordance with another study in Italy that analyzed patients with acute respiratory distress syndrome (ARDS) admitted to the ICU, mortality related to carbapenemase-producing *Klebsiella pneumonia* was reported as high as 28.6%. Previous studies also reported that gram-negative bacteria were associated with longer hospital stay, longer ICU stay, mechanical ventilator use, and higher mortality. This study also showed that older age was associated with a higher risk of mortality, as shown in previous studies, because older adults usually have a more complicated condition that prolongs hospitalization duration. It makes them more vulnerable to contracting secondary bacterial or nosocomial infections. Critical patients with respiratory failure or acute respiratory distress syndrome require higher levels of oxygen therapy, such as use of ventilators, which are associated with a higher risk of mortality and increased risk of secondary bacterial infection.

This study has some limitations. The true rate of secondary pulmonary bacterial infection is likely to be higher than that reported in this study because of the retrospective nature of the study, and PCT testing was not routinely and uniformly performed at the same time. Another limitation was the isolation of anaerobic, atypical, and fastidious microorganisms that were not recorded in this study. Clinical symptoms are important in making decisions regarding the possibility of infection, initiation, and choice of antibiotics; hence, it is possible that PCT and bacterial microbiological examinations were not performed in patients with relatively mild symptoms, especially in patients who had been administered empiric antibiotics, which may produce inaccurate findings.

### Conclusion

This study reveals that gram-negative bacteria are pathogens causing secondary lung infections in hospitalized COVID-19 patients, with *A. baumannii* as the most common pathogen, implying a nosocomial infection. High resistance to first-line antimicrobial drugs (fluoroquinolone) was observed in Gram-negative bacteria and Gram-positive bacteria. High rate of MDR pathogens was found among isolate and was associated with a significant risk of mortality.

### Acknowledgments

We would like to express our gratitude to all the health workers in both hospitals for their service and sacrifice during the COVID-19 pandemic. We acknowledge the helpful input from Evan Susandi in this study. Financial support for the study was provided by Universitas Padjadjaran (grant No. 1735/UN6.3.1/LT/2020).

| Variable          | Initial Model | Final Model |
|-------------------|---------------|-------------|
|                  | AOR (95% CI AOR) | p-value     | AOR (95% CI AOR) | p-value     |
| Age (≥60 years)   | 4.20 (1.67–10.54) | 0.002*      | 4.03 (1.63–9.98) | 0.003*      |
| Sex (female)      | 2.73 (1.06–7.02)  | 0.037*      | 2.59 (1.02–6.57) | 0.045*      |
| Comorbidity (any) | 0.80 (0.30–2.12)  | 0.651       | 0.80 (0.30–2.12)  | 0.651       |
| Ventilator        | 3.08 (0.81–11.73) | 0.100       | 4.07 (1.20–13.80) | 0.024*      |
| Severity (severe) | 1.77 (0.67–4.68)  | 0.251       | 1.77 (0.67–4.68)  | 0.251       |
| MDR pathogens     | 5.64 (2.09–15.20) | 0.001*      | 5.63 (2.12–14.93) | 0.001*      |

*Note:* *Statistically significant.*

*Abbreviations:* AOR, adjusted odds ratio; CI, confidence interval; COVID-19, coronavirus disease.
Disclosure

The authors report no conflicts of interest in this work.

References

1. CDC. COVID-19 case surveillance public use data; 2021.
2. Tian R, Wu W, Wang C, et al. Clinical characteristics and survival outcomes of COVID-19 patients in Wuhan, China: a single-center retrospective case control study. Sci Rep. 2020;10(1):1–8. doi:10.1038/s41598-020-74465-3
3. Rozaliyani A, Savirini AI, Setianingrum F, et al. Factors associated with death in COVID-19 patients in Jakarta, Indonesia: an epidemiological study. Acta Med Indones. 2020;52(3):246–254.
4. Surendra H, Elazar Y, Djaafara BA, et al. Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: a hospital-based retrospective cohort study. Lancet Reg Health West Pac. 2021;9:100108. doi:10.1016/j.lanwpc.2021.100108
5. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi:10.1016/S0140-6736(20)30566-3
6. Shang J, Wang Q, Zhang H, et al. The relationship between diabetes mellitus and COVID-19 prognosis: a retrospective cohort study in Wuhan, China. Am J Med. 2021;134(1):e6–e14. doi:10.1016/j.amjmed.2020.05.033
7. Shi Q, Zhang X, Jiang F, et al. Clinical characteristics and risk factors for mortality of COVID-19 patients with diabetes in Wuhan, China: a two-center, retrospective study. Diabetes Care. 2020;43(7):1382–1391. doi:10.2337/dc20-0598
8. Zhi J, Wang X, Jia X, et al. Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China. Clin Microbiol Infect. 2020;26(6):767–772. doi:10.1016/j.cmi.2020.04.012
9. Morris DE, Clevy DW, Clarke SC. Secondary bacterial infections associated with influenza pandemics. Front Microbiol. 2017;8:1041. doi:10.3389/fmicb.2017.01041
10. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis. 2008;198(7):962–970. doi:10.1086/591708
11. Louria DB, Blumenfeld HL, Ellis JT, Kilbourne ED, Rogers DE. Studies on influenza in the pandemic of 1957–1958. II. Pulmonary complications of influenza. J Clin Invest. 1959;38(1):213–265. doi:10.1172/JCI1103791
12. Weinberger DM, Simonsen L, Jordan R, Steiner C, Miller M, Viboud C. Impact of the 2009 influenza pandemic on pneumococcal pneumonia hospitalizations in the United States. J Infect Dis. 2012;205(3):458–465. doi:10.1093/infdis/jir279
13. Li J, Wang J, Yang Y, et al. Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: a retrospective analysis. Antimicrob Resist Infect Control. 2020;9(1):1–7. doi:10.1186/s13756-020-00081-7
14. Cheng LS-K, Chau SK-Y, Tso EY-K, et al. Bacterial co-infections and antibiotic prescribing practice in adults with COVID-19: experience from a single hospital cluster. Ther Adv Infect Dis. 2020;7:204936120978895. doi:10.1177/204936120978895
15. Martinez-Guerra BA, Gonzalez-Lara MF, De-leon-cividanes NA, et al. Antimicrobial resistance patterns and antibiotic use during hospital conversion in the COVID-19 pandemic. Antibiotics. 2021;10(2):182. doi:10.3390/antibiotics10020182
16. Langford BJ, So M, Raybardhan S, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020;26:1622–1629. doi:10.1016/j.cmi.2020.07.016
17. Vaughan VM, Gandhi TN, Petty LA, et al. Empiric antibacterial therapy and community-onset bacterial coinfection in patients hospitalized with coronavirus disease 2019 (COVID-19): a multi-hospital cohort study. Clin Infect Dis. 2021;72(10):e533–e541. doi:10.1093/cid/ciaa1239
18. Dieringer TD, Furukawa D, Graber CJ, et al. Inpatient antibiotic utilization in the veterans’ health administration during the coronavirus disease 2019 (COVID-19) pandemic. Infect Control Hosp Epidemiol. 2021;42(6):751–753. doi:10.1086/717728
19. Buehrle DJ, Decker BK, Wagener MM, et al. Antibiotic consumption and stewardship at a hospital outside of an early coronavirus disease 2019 epicenter. Antimicrob Agents Chemother. 2020;64:e01101-20. doi:10.1128/AAC.01101-20
20. Staub MB, Beaulieu RM, Graves J, Nelson GE. Changes in antimicrobial utilization during the coronavirus disease 2019 (COVID-19) pandemic after implementation of a multispecialty clinical guidance team. Infect Control Hosp Epidemiol. 2021;42(7):810–816. doi:10.1017/ice.2020.1291
21. Costa R, Lamas C, Simvoulidis LFN, et al. Secondary infections in a cohort of patients with COVID-19 admitted to an intensive care unit: impact of gram-negative bacterial resistance. Rev Inst Med Trop Sao Paulo. 2020;62(4):239–246. doi:10.20926/rimtsp-2020-3403
22. Murray P, Washington J. Microscopic and bacteriologic examination of expectorated sputum; 1975: 339–344.
23. World Health Organization. Global antimicrobial resistance surveillance system (GLASS) report: early implementation 2016–2017; 2017.
24. Whelton PK, Williams B. The 2018 European Society of Cardiology/European Society of Hypertension and 2017 American College of Cardiology/American heart association blood pressure guidelines: more Similar s. JAMA. 2018;320(17):1749–1750. doi:10.1001/jama.2018.16755
25. World Health Organization. The Asia-Pacific perspective: redefining obesity and its treatment; 2000.
26. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2009;32(Supplement_1):S62–S67. doi:10.2337/dc09-S062
27. Levey AS, Eckardt K-U, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int. 2005;67(6):2089–2100. doi:10.1111/j.1523-1755.2005.00365.x
28. Magiorakos A-P, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281. doi:10.1111/j.1469-0691.2011.03570.x
29. Lian J, Jin X, Hao S, et al. Analysis of epidemiological and clinical features in older patients with coronavirus disease 2019 (COVID-19) outside Wuhan. Clin Infect Dis. 2020;71(15):740–747. doi:10.1093/cid/ciaa242
30. World Health Organization. COVID-19 clinical management: living guidance; 2020.
32. Paget C, Trottle F. Mechanisms of bacterial superinfection post-influenza: a role for unconventional T cells. Front Immunol. 2019;10:336. doi:10.3389/fimmu.2019.00336

33. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395 (10223):497–506. doi:10.1016/S0140-6736(20)30183-5

34. Karaş M, Duman MY, Tünger A, Çilli F, Aydemir Ş, Ozenci V. Secondary bacterial infections and antimicrobial resistance in COVID-19: comparative evaluation of pre-pandemic and pandemic-era, A retrospective single center study. Ann Clin Microbiol Antimicrob. 2021;20. doi:10.1186/s12941-021-00454-7

35. Strathdee SA, Davies SC, Marcellin JR. Confronting antimicrobial resistance beyond the COVID-19 pandemic and the 2020 US election. Lancet. 2020;396(10257):1050–1053. doi:10.1016/S0140-6736(20)32063-8

36. Vijay S, Bansal N, Rao BK, et al. Secondary infections in hospitalized COVID-19 patients: Indian experience. Infect Drug Resist. 2021;14:1893. doi:10.2147/IDR.S299774

37. De Santis V, Corona A, Vitale D, et al. Bacterial infections in critically ill patients with SARS-2-COVID-19 infection: results of a prospective observational multicenter study. Infection. 2022;50(1):139–148. doi:10.1007/s15010-021-01661-2

38. Khurana S, Singh P, Sharad N, et al. Profile of co-infections & secondary infections in COVID19 patients at a dedicated COVID-19 facility of a tertiary care Indian hospital: implication on antimicrobial resistance. Indian J Med Microbiol. 2021;39(2):147–153. doi:10.1016/j.ijjmmh.2020.10.014

39. Bardi T, Pintado V, Gomez-Rojo M, et al. Nosocomial infections associated to COVID-19 in the intensive care unit: clinical characteristics and outcome. Eur J Clin Microbiol Infect Dis. 2021;40(3):495–502. doi:10.1007/s10096-020-04142-w

40. Koulenti D, Tsigou E, Rello J. Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP/CAP study. Eur j Clin Microbiol Infect Dis. 2017;36(11):1999–2006. doi:10.1007/s10096-016-2703-z

41. Garcia-Vidal C, Sanjuan G, Moreno-Garcia E, et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microb Infect. 2021;27(1):83–88. doi:10.1016/j.cmi.2020.07.041

42. Sanchez GV, Master RN, Clark RB, et al. Klebsiella pneumoniae antimicrobial drug resistance, United States, 1998–2010. Emerg Infect Dis. 2013;19(1):133. doi:10.3201/eid1901.120310

43. McDonald LC. Trends in antimicrobial resistance in health care-associated pathogens and effect on treatment. Clin Infect Dis. 2006;42 (Supplement 2):S65–S71. doi:10.1086/499404

44. Yu Y-S, Yang Q, Xu X-W, Kong H-S, Zhong B-Y. Typing and characterization of carbapenem-resistant Acinetobacter baumannii complex in a Chinese hospital. J Med Microbiol. 2004;53(7):653–656. doi:10.1099/jmm.0.05513-0

45. Hsueh P-R, Liu Y-C, Yang D, et al. Multicenter surveillance of antimicrobial resistance of major bacterial pathogens in intensive care units in 2000 in Taiwan. Microb Drug Resist. 2001;7(4):373–382. doi:10.1089/10766290152773383

46. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302 (21):2323–2329. doi:10.1001/jama.2009.1754

47. Abbas M, Nunes TR, Martischang R, et al. Nosocomial transmission and outbreaks of coronavirus disease 2019: the need to protect both patients and healthcare workers. Antimicrob Resist Infect Control. 2021;10(1):1–13. doi:10.1186/s13756-020-00875-7

48. Almasaudi SB. Acinetobacter spp. as nosocomial pathogens: epidemiology and resistance features. Saudi J Biol Sci. 2018;25(3):586–596. doi:10.1016/j.sjbs.2016.02.009

49. Lindberg M, Skytt B, Lindberg M. Continued wearing of gloves: a risk behaviour in patient care. Infect Prev Pract. 2020;2(4):10091. doi:10.1016/ j.ipinf.2020.10091

50. Montrucchio G, Corcione S, Sales G, Curtoni A, De Rosa F, Brazzi L. Carbapenem-resistant Klebsiella pneumoniae in ICU-admitted COVID-19 patients: keep an eye on the ball. J Glob Antimicrob Resist. 2020;23:398–400. doi:10.1016/j.jgar.2020.11.004

51. Zhang J, Yu L, Fu Y, et al. Tigecycline in combination with other antibiotics against clinical isolates of carbapenem-resistant Klebsiella pneumoniae in vitro. Ann Palliat Med. 2019;8(5):622–631. doi:10.21037/apm.2019.09.11

52. Ali MM, Malik MR, Ahmed AY, et al. Survival analysis of all critically ill patients with COVID-19 admitted to the main hospital in Mogadishu, Somalia, 30 March–12 June 2020: which interventions are proving effective in fragile states? Int J Infect Dis. 2022;114:202–209. doi:10.1016/j.ijid.2021.11.018

53. Sousa G, Garces T, Cestari V, Florêncio R, Pereira M. Mortality and survival of COVID-19. Epidemiol Infect. 2020;148. doi:10.1017/ S0950268820001405

54. De Smet R, Mellaerts B, Vandewinckele H, et al. Frailty and mortality in hospitalized older adults with COVID-19: retrospective observational study. J Am Med Dir Assoc. 2020;21(7):928–932. e1. doi:10.1016/j.jamda.2020.06.008

55. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–481. doi:10.1016/S2213-2600(20)30079-5